osteoporosis prevention
Women's health · 2024–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| estradiol; progesterone; estradiol and progesterone Treatment of menopausal vasomotor symptoms (hot flushes) in postmenopausal women; prevention of osteoporosis in postmenopausal women at high risk; adjunctive… | Nov 2024 | Recommended with restriction | 108 individuals Research Institute · Inherited Cancers Australia |
Who spoke
Research Institute · Inherited Cancers Australia
What the PBS pays
$32M in government benefit over 2024–25, across 1,180,562 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| estradiol; progesterone; estradiol and progesterone combination | $31.6M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 0 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| raloxifeneRaloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women | TA160 | unknown | 2008-10 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.